<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02367989</url>
  </required_header>
  <id_info>
    <org_study_id>1333</org_study_id>
    <nct_id>NCT02367989</nct_id>
  </id_info>
  <brief_title>Effects of Barley on Glucose Control</brief_title>
  <official_title>A Dose-response, Double-blind, Randomized, Controlled, Cross-over Trial Examining the Effect of Barley Beta-glucan on Post-prandial Glucose Response in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Boniface General Hospital Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agriculture and Agri-Food Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Boniface General Hospital Research Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lifestyle modifications that include a diet high in fibre may lower the risk of developing
      type 2 diabetes (CDA, 2013). In this context, the presence of soluble dietary fibre in
      carbohydrate rich foods has been widely recognized for its effect on post-prandial glucose
      response (PPGR). Among these, oat and barley derived β-glucan have received tremendous
      attention for their biological effects, including their ability to reduce PPGR in a wide
      variety of food matrices (Poppitt et al, 2007). A health claim for PPGR would increase market
      demand for food grade barley, and help those who want to limit the rise in blood sugar after
      a meal choose products to meet their goals, but there are several gaps in the literature that
      need to be filled before a submission to Health Canada can be successful: 1) test foods in
      appropriate serving sizes; 2) test both the glucose and insulin response; 3) include a
      reference product that matches in total fibre, macronutrient, and energy profile; 4) perform
      dose response. The proposed study design will address all of these gaps in the current
      literature and take into consideration Health Canada's guidance document for health claims
      related to the reduction in PPGR, which sets out the criteria by which the validity of such
      claims will be assessed.

      Hypothesis:

      Barley β-glucan will reduce the PPGR in healthy participants in a dose dependent manner.

      Specific objectives:

        1. To determine the minimum and most effective dose of barley β-glucan in waffles on PPGR
           and insulin response in a cross-over, randomized, controlled clinical trial.

        2. To assess the effect of barley β-glucan in waffles on appetite-related sensations using
           visual analog scales.

        3. To demonstrate whether the test and reference products were liked or disliked similarly
           by participants.

        4. To assess any gastrointestinal side effects from eating the test products
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, controlled, cross-over study designed to examine the PPGR to
      barley β-glucan will be conducted at the I.H. Asper Clinical Research Institute in Winnipeg,
      Manitoba. A total of 24 healthy volunteers will participate in the trial. Eligible
      participants who have provided consent will be asked to attend 5 clinic visits in a fasted
      state. At each visit hey will be given 1 set of waffles to eat that contains either 0g, 2g,
      4g, or 6g of barley β-glucan, 7 finger pokes to collect capillary blood, 5 questionnaires
      about their appetite and a questionnaire about the acceptability of the quick bread. Each
      visit will last approximately 2.5h and be separated by 3-14 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-prandial glucose response</measure>
    <time_frame>120 minutes</time_frame>
    <description>Incremental area under the curve for glucose (mmol*min/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-prandial insulin response</measure>
    <time_frame>120 min</time_frame>
    <description>Incremental area under the curve for insulin (uIU*min/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hunger</measure>
    <time_frame>120 min</time_frame>
    <description>total area under the curve (AUC) using visual analog scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fullness</measure>
    <time_frame>120 min</time_frame>
    <description>total area under the curve (AUC) using visual analog scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>desire to eat</measure>
    <time_frame>120 min</time_frame>
    <description>total area under the curve (AUC) using visual analog scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prospective consumption</measure>
    <time_frame>120 min</time_frame>
    <description>total area under the curve (AUC) using visual analog scales</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acceptability of waffle color</measure>
    <time_frame>15 min</time_frame>
    <description>Ratings on a scale of 1-9</description>
  </other_outcome>
  <other_outcome>
    <measure>Acceptability of waffle aroma</measure>
    <time_frame>15 min</time_frame>
    <description>Ratings on a scale of 1-9</description>
  </other_outcome>
  <other_outcome>
    <measure>Acceptability of waffle flavor</measure>
    <time_frame>15 min</time_frame>
    <description>Ratings on a scale of 1-9</description>
  </other_outcome>
  <other_outcome>
    <measure>Acceptability of waffle texture</measure>
    <time_frame>15 min</time_frame>
    <description>Ratings on a scale of 1-9</description>
  </other_outcome>
  <other_outcome>
    <measure>Acceptability of waffle frequency of consumption</measure>
    <time_frame>15 min</time_frame>
    <description>Ratings on a scale of 1-9</description>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal side effects</measure>
    <time_frame>120 min</time_frame>
    <description>self reporting incidence of gastrointestinal effects</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Control without fibre</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: 0g barley β-glucan no fibre.
Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low barley β-glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 2g barley β-glucan
Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medium barley β-glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 4g barley β-glucan
Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high barley β-glucan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: 6g barley β-glucan
Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control with fibre</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: 0g barley β-glucan with fibre
Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>0g barley β-glucan no fibre</intervention_name>
    <description>Food containing no barley β-glucan and no additional fibre</description>
    <arm_group_label>Control without fibre</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>2g barley β-glucan</intervention_name>
    <description>Food containing low amounts of barley β-glucan</description>
    <arm_group_label>low barley β-glucan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>4g barley β-glucan</intervention_name>
    <description>Food containing medium amounts of barley β-glucan</description>
    <arm_group_label>medium barley β-glucan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>6g barley β-glucan</intervention_name>
    <description>Food containing high amounts of barley β-glucan</description>
    <arm_group_label>high barley β-glucan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>0g barley β-glucan with fibre</intervention_name>
    <description>Food containing no barley β-glucan, but matches fibre content in β-glucan treatments</description>
    <arm_group_label>control with fibre</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Generally healthy male or female, between the age of 18-40 years;

          2. Body mass index (BMI) 18.5-30.0 kg/m2;

          3. Habitually consume breakfast, lunch and dinner in the morning, mid-day and evening,
             respectively;

          4. Willing to provide informed consent;

          5. Willing/able to comply with the requirements of the study.

        Exclusion Criteria:

          1. Pregnant or lactating;

          2. Medical history of diabetes mellitus, fasting plasma glucose ≥7.0 mmol/L, HbA1c ≥6.0%,
             or use of insulin or oral medication to control blood sugar;

          3. Medical history of cardiovascular disease;

          4. Systolic blood pressure &gt;140 mm Hg or diastolic blood pressure &gt;90 mm Hg;

          5. Fasting plasma total cholesterol &gt;7.8 mmol/L;

          6. Fasting plasma HDL &lt;0.9 mmol/L;

          7. Fasting plasma LDL &gt;5.0 mmol/L;

          8. Fasting plasma triglycerides &gt;2.3 mmol/L;

          9. Major surgery within the last 3 months;

         10. Medical history of inflammatory disease (ie. Systemic lupus erythematosis, rheumatoid
             arthritis, psoriasis) or use of any corticosteroid medications within 3 months;

         11. Medical history of liver disease or liver dysfunction (defined as plasma AST or ALT
             ≥1.5 times the upper limit of normal (ULN));

         12. Medical history of kidney disease or kidney dysfunction (defined as blood urea
             nitrogen and creatinine ≥ 1.8 times the ULN));

         13. Presence of a gastrointestinal disorder, daily use of any stomach acid-lowering
             medications or laxatives (including fibre supplements) within the past month or
             antibiotic use with the past 6 weeks;

         14. Active treatment for any type of cancer within 1 year prior to study start;

         15. Other medical, psychiatric, or behavioral factors that in the judgment of the
             principal Investigator may interfere with study participation or the ability to follow
             the intervention protocol;

         16. Shift worker (a system of employment where an individual's normal hours of work are in
             part, outside the period of normal working day; 6am and 8pm);

         17. Smoking, use of tobacco or a nicotine replacement product (within the last 3 months);

         18. Allergies to barley or wheat flour;

         19. Aversion or unwillingness to eat study foods;

         20. Use of any prescription or non-prescription drug, herbal or nutritional supplement
             known to affect glycemia;

         21. Participation in another clinical trial, current or in the past 4 weeks;

         22. Unstable body weight (defined as &gt;5% change in 3 months) or actively participating in
             a weight loss program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Blewett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Agriculture and Agri-Food Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heather Blewett, Ph.D</last_name>
    <phone>(204) 237-2954</phone>
    <email>hblewett@sbrc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jay Petkau</last_name>
    <phone>(204) 258-1209</phone>
    <email>jpetkau@sbrc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>I.H. Asper Clinical Research Institute</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Blewett, Ph.D</last_name>
      <phone>204-237-2954</phone>
      <email>hblewett@sbrc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jay Petkau</last_name>
      <email>jpetkau@sbrc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Nancy Ames, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sora Ludwig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Ames NP, Rhymer CR. Issues surrounding health claims for barley. J Nutr. 2008 Jun;138(6):1237S-43S. Review.</citation>
    <PMID>18492863</PMID>
  </reference>
  <reference>
    <citation>Aziz A, Dumais L, Barber J. Health Canada's evaluation of the use of glycemic index claims on food labels. Am J Clin Nutr. 2013 Aug;98(2):269-74. doi: 10.3945/ajcn.113.061770. Epub 2013 Jun 12. Review.</citation>
    <PMID>23761481</PMID>
  </reference>
  <reference>
    <citation>Biörklund M, van Rees A, Mensink RP, Onning G. Changes in serum lipids and postprandial glucose and insulin concentrations after consumption of beverages with beta-glucans from oats or barley: a randomised dose-controlled trial. Eur J Clin Nutr. 2005 Nov;59(11):1272-81.</citation>
    <PMID>16015250</PMID>
  </reference>
  <reference>
    <citation>Casiraghi MC, Garsetti M, Testolin G, Brighenti F. Post-prandial responses to cereal products enriched with barley beta-glucan. J Am Coll Nutr. 2006 Aug;25(4):313-20.</citation>
    <PMID>16943453</PMID>
  </reference>
  <reference>
    <citation>Chillo S, Ranawana DV, Pratt M, Henry CJ. Glycemic response and glycemic index of semolina spaghetti enriched with barley β-glucan. Nutrition. 2011 Jun;27(6):653-8. doi: 10.1016/j.nut.2010.07.003. Epub 2010 Sep 24.</citation>
    <PMID>20869206</PMID>
  </reference>
  <reference>
    <citation>de Graaf C, Blom WA, Smeets PA, Stafleu A, Hendriks HF. Biomarkers of satiation and satiety. Am J Clin Nutr. 2004 Jun;79(6):946-61. Review.</citation>
    <PMID>15159223</PMID>
  </reference>
  <reference>
    <citation>Poppitt SD, van Drunen JD, McGill AT, Mulvey TB, Leahy FE. Supplementation of a high-carbohydrate breakfast with barley beta-glucan improves postprandial glycaemic response for meals but not beverages. Asia Pac J Clin Nutr. 2007;16(1):16-24.</citation>
    <PMID>17215176</PMID>
  </reference>
  <reference>
    <citation>Thondre PS, Henry CJ. Effect of a low molecular weight, high-purity β-glucan on in vitro digestion and glycemic response. Int J Food Sci Nutr. 2011 Nov;62(7):678-84. doi: 10.3109/09637486.2011.566849. Epub 2011 May 12.</citation>
    <PMID>21561391</PMID>
  </reference>
  <reference>
    <citation>Thondre PS, Wang K, Rosenthal AJ, Henry CJ. Glycaemic response to barley porridge varying in dietary fibre content. Br J Nutr. 2012 Mar;107(5):719-24. doi: 10.1017/S0007114511003461. Epub 2011 Jul 26.</citation>
    <PMID>21787456</PMID>
  </reference>
  <reference>
    <citation>Tosh SM. Review of human studies investigating the post-prandial blood-glucose lowering ability of oat and barley food products. Eur J Clin Nutr. 2013 Apr;67(4):310-7. doi: 10.1038/ejcn.2013.25. Epub 2013 Feb 20. Review.</citation>
    <PMID>23422921</PMID>
  </reference>
  <reference>
    <citation>Canadian Diabetes Association. Canadian diabetes association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes. 2008;32(1).</citation>
  </reference>
  <reference>
    <citation>Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Cheng AY. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J Diabetes. 2013 Apr;37 Suppl 1:S1-3. doi: 10.1016/j.jcjd.2013.01.009. Epub 2013 Mar 26.</citation>
    <PMID>24070926</PMID>
  </reference>
  <reference>
    <citation>Health Canada. Summary of health Canada's assessment of a health claim about barley products and blood cholesterol lowering. [Internet].; 2012. Available from: http://www.hc-sc.gc.ca/fn-an/label-etiquet/claims-reclam/assess-evalu/barley-orge-eng.php.</citation>
  </reference>
  <reference>
    <citation>European Food Safety Authority. Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations. EFSA Journal. 2012;10(3):2604.</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Boniface General Hospital Research Centre</investigator_affiliation>
    <investigator_full_name>Dr. Heather Blewett</investigator_full_name>
    <investigator_title>Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Glucose response</keyword>
  <keyword>Insulin response</keyword>
  <keyword>Satiety</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

